Evidence map›Paper›PMID 33028251›Full record

ArticleBMC cancer2020

Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.

Alyssa A Hoover, Demetra H Hufnagel, Whitney Harris, Kennady Bullock, Evan B Glass, Esther Liu, Whitney Barham, Marta A Crispens, Dineo Khabele, Todd D Giorgio and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Alyssa A Hoover *Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
Demetra H Hufnagel *Vanderbilt University School of Medicine, Nashville, TN, USA.
Whitney HarrisDepartment of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
Kennady BullockDepartment of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
Evan B GlassDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Esther LiuDepartment of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
Whitney BarhamDepartment of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
Marta A CrispensDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Dineo KhabeleDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Todd D GiorgioDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Andrew J WilsonDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Fiona E YullDepartment of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA. fiona.yull@vanderbilt.edu.ORCID 0000-0003-1636-7942
Vanderbilt University · USWashington University in St. Louis · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
Macrophage-based ovarian cancer immunotherapyR01CA214043 · NCI · VANDERBILT UNIVERSITY · PI GIORGIO, TODD D, KHABELE, DINEO · 2017 to 2021
$1.9M
Burroughs Wellcome Fund 1018894NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA214043NIDDK NIH HHS U24 DK059637NIGMS NIH HHS T32 GM007628
6 · The paper itself

Abstract

backgroundNew treatment options for ovarian cancer are urgently required. Tumor-associated macrophages (TAMs) are an attractive target for therapy; repolarizing TAMs from M2 (pro-tumor) to M1 (anti-tumor) phenotypes represents an important therapeutic goal. We have previously shown that upregulated NF-kappaB (NF-κB) signaling in macrophages promotes M1 polarization, but effects in the context of ovarian cancer are unknown. Therefore, we aimed to investigate the therapeutic potential of increasing macrophage NF-κB activity in immunocompetent mouse models of ovarian cancer.

methodsWe have generated a transgenic mouse model, termed IKFM, which allows doxycycline-inducible overexpression of a constitutively active form of IKK2 (cIKK2) specifically within macrophages. The IKFM model was used to evaluate effects of increasing macrophage NF-κB activity in syngeneic murine TBR5 and ID8-Luc models of ovarian cancer in two temporal windows: 1) in established tumors, and 2) during tumor implantation and early tumor growth. Tumor weight, ascites volume, ascites supernatant and cells, and solid tumor were collected at sacrifice. Populations of macrophages and T cells within solid tumor and/or ascites were analyzed by immunofluorescent staining and qPCR, and soluble factors in ascitic fluid were analyzed by ELISA. Comparisons of control versus IKFM groups were performed by 2-tailed Mann-Whitney test, and a P-value < 0.05 was considered statistically significant.

resultsIncreased expression of the cIKK2 transgene in TAMs from IKFM mice was confirmed at the mRNA and protein levels. Tumors from IKFM mice, regardless of the timing of doxycycline (dox) administration, demonstrated greater necrosis and immune infiltration than control tumors. Analysis of IKFM ascites and tumors showed sustained shifts in macrophage populations away from the M2 and towards the anti-tumor M1 phenotype. There were also increased tumor-infiltrating CD3

conclusionsIn syngeneic ovarian cancer models, increased canonical NF-κB signaling in macrophages promoted anti-tumor TAM phenotypes and increased cytotoxic T cell infiltration, which was sufficient to limit tumor progression. This may present a novel translational approach for ovarian cancer treatment, with the potential to increase responses to T cell-directed therapy in future studies.

Indexed as

AnimalsCell Line, TumorDisease Models, AnimalDisease ProgressionFemaleHumansMacrophagesMiceMice, TransgenicNF-kappa BSignal TransductionNF-kappa BNF-κBOvarian cancerTumor immunology

Identifiers

PMID33028251
PMCPMC7542116
OpenAlexW3092622132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.